- Global Pharma News & Resources

Foundation for the Industry's Next-stage Innovation and Growth

Foundation for the Industry's Next-stage Innovation and Growth

New lab in North America / Burlington BioCenter 4 Burlington Woods Drive Burlington, MA

(PresseBox) (Burlington, MA, 06.07.2022) 

ProtaGene is thrilled to announce the planned opening of our brand-new, state-of-the-art lab and office headquarters in the Burlington BioCenter, located in Boston’s rapidly growing biotechnology hub.

Our expanded footprint is designed to enable new capabilities required to advance today’s biologic and gene therapy platforms and provide additional capacity to meet the growing demand for our analytical services across all biotherapeutic sectors.

The new facility will feature:

- 27,000 square feet of brand-new Class-A lab and office space - triple the size of our current facility
- Custom-designed protein and gene analytic labs, systems, and workflows
- Centrally located Sample receiving, log-in, storage and monitoring
- Facility and systems designed to run under advanced Quality Systems
- Expanded biologic drug analytics capacity
- Enhanced vector analytics, gene expression analysis, and genetic and analysis capacity
- Addition of GeneWerk Integration Site Analysis - essential for assessing the biosafety of gene therapy vectors throughout their development and regulatory approval proccessed

Advanced Analytical Services Lab

ProtaGene’s new laboratory will be positioned centrally among the over 400 leading biopharma companies in Massachusetts, allowing ample opportunities for direct partnered development programs with some of the industry’s best and brightest.

Our planned move from our current site at 790 Memorial Drive in Cambridge will be in controlled phases to ensure full analytic, operational and project continuity from one site to the next. Thoughtful and strict planning has been undertaken to minimize disruptions through the transition.

Editor Details

Last Updated: 06-Jul-2022